19. Swenson DL, Wang D, Luo M, Warfield KL, Woraratanadharm J, et al. (2008) Vaccine to confer to nonhuman primates complete protection against multistrain ebola and marburg virus infections. Clin Vaccine Immunol 15(3): 460–467. 20. Bukreyev A, Rollin PE, Tate MK, Yang L, Zaki SR, et al. (2007) Successful topical respiratory tract immunization of primates against ebola virus. J Virol 81(12): 6379–6388. 21. Bukreyev A, Marzi A, Feldmann F, Zhang L, Yang L, et al. (2008) Chimeric human parainfluenza virus bearing the ebola virus glycoprotein as the sole surface protein is immunogenic and highly protective against ebola virus challenge. Virology 383(2): 348–361. 22. Sullivan NJ, Sanchez A, Rollin PE, Yang ZY, Nabel GJ (2000) Development of a preventive vaccine for ebola virus infection in primates. Nature 408(6812): 605–609. 23. Sullivan NJ, Geisbert TW, Geisbert JB, Xu L, Yang ZY, et al. (2003) Accelerated vaccination for ebola virus haemorrhagic fever in non-human primates. Nature 424(6949): 681–684. 24. Sullivan NJ, Geisbert TW, Geisbert JB, Shedlock DJ, Xu L, et al. (2006) Immune protection of nonhuman primates against ebola virus with single low- dose adenovirus vectors encoding modified GPs. PLoS Med 3(6): e177. 25. Jones SM, Feldmann H, Stroher U, Geisbert JB, Fernando L, et al. (2005) Live attenuated recombinant vaccine protects nonhuman primates against ebola and marburg viruses. Nat Med 11(7): 786–790. 26. Daddario-DiCaprio KM, Geisbert TW, Geisbert JB, Stroher U, Hensley LE, et al. (2006) Cross-protection against marburg virus strains by using a live, attenuated recombinant vaccine. J Virol 80(19): 9659–9666. 27. Garbutt M, Liebscher R, Wahl-Jensen V, Jones S, Moller P, et al. (2004) Properties of replication-competent vesicular stomatitis virus vectors expressing glycoproteins of filoviruses and arenaviruses. J Virol 78(10): 5458–5465. 28. Geisbert TW, Jones S, Fritz EA, Shurtleff AC, Geisbert JB, et al. (2005) Development of a new vaccine for the prevention of lassa fever. PLoS Med 2(6): e183. 29. Ebihara H, Theriault S, Neumann G, Alimonti JB, Geisbert JB, et al. (2007) In vitro and in vivo characterization of recombinant ebola viruses expressing enhanced green fluorescent protein. J Infect Dis 196 Suppl 2: S313–22. 30. Gupta M, Spiropoulou C, Rollin PE (2007) Ebola virus infection of human PBMCs causes massive death of macrophages, CD4 and CD8 T cell sub- populations in vitro. Virology 364(1): 45–54. 31. Reed DS, Hensley LE, Geisbert JB, Jahrling PB, Geisbert TW (2004) Depletion of peripheral blood T lymphocytes and NK cells during the course of ebola hemorrhagic fever in cynomolgus macaques. Viral Immunol 17(3): 390–400. 32. Geisbert TW, Hensley LE, Gibb TR, Steele KE, Jaax NK, et al. (2000) Apoptosis induced in vitro and in vivo during infection by ebola and marburg viruses. Lab Invest 80(2): 171–186. Ebola Specific Immune Response 33. Stroher U, West E, Bugany H, Klenk HD, Schnittler HJ, et al. (2001) Infection and activation of monocytes by marburg and ebola viruses. J Virol 75(22): 11025–11033. 34. Gupta M, Mahanty S, Ahmed R, Rollin PE (2001) Monocyte-derived human macrophages and peripheral blood mononuclear cells infected with ebola virus secrete MIP-1alpha and TNF-alpha and inhibit poly-IC-induced IFN-alpha in vitro. Virology 284(1): 20–25. 35. Pushko P, Bray M, Ludwig GV, Parker M, Schmaljohn A, et al. (2000) Recombinant RNA replicons derived from attenuated venezuelan equine encephalitis virus protect guinea pigs and mice from ebola hemorrhagic fever virus. Vaccine 19(1): 142–153. 36. Vanderzanden L, Bray M, Fuller D, Roberts T, Custer D, et al. (1998) DNA vaccines expressing either the GP or NP genes of ebola virus protect mice from lethal challenge. Virology 246(1): 134–144. 37. Rao M, Bray M, Alving CR, Jahrling P, Matyas GR (2002) Induction of immune responses in mice and monkeys to ebola virus after immunization with liposome-encapsulated irradiated ebola virus: Protection in mice requires CD4(+) T cells. J Virol 76(18): 9176–9185. 38. Bradfute SB, Braun DR, Shamblin JD, Geisbert JB, Paragas J, et al. (2007) Lymphocyte death in a mouse model of ebola virus infection. J Infect Dis 196 Suppl 2: S296–304. 39. Schroder K, Hertzog PJ, Ravasi T, Hume DA (2004) Interferon-gamma: An overview of signals, mechanisms and functions. J Leukoc Biol 75(2): 163–189. 40. Jones SM, Stroher U, Fernando L, Qiu X, Alimonti J, et al. (2007) Assessment of a vesicular stomatitis virus-based vaccine by use of the mouse model of ebola virus hemorrhagic fever. J Infect Dis 196 Suppl 2: S404–12. 41. Feldmann H, Jones SM, Daddario-DiCaprio KM, Geisbert JB, Stroher U, et al. (2007) Effective post-exposure treatment of ebola infection. PLoS Pathog 3(1): e2. 42. Peters CJ, Sanchez A, Rollin PE, Ksiazek T, Murphy FA (1996) Filoviridae: Marburg and ebola viruses. In: Fields BM, Knipe DM, Howley PM, eds. Fields Virology. New York, NY: Raven Press. pp 1161. 43. Leffel EK, Reed DS (2004) Marburg and ebola viruses as aerosol threats. Biosecur Bioterror 2(3): 186–191. 44. Schnell MJ, Buonocore L, Kretzschmar E, Johnson E, Rose JK (1996) Foreign glycoproteins expressed from recombinant vesicular stomatitis viruses are incorporated efficiently into virus particles. Proc Natl Acad Sci U S A 93(21): 11359–11365. 45. Jahrling PB, Geisbert TW, Geisbert JB, Swearengen JR, Bray M, et al. (1999) Evaluation of immune globulin and recombinant interferon-alpha2b for treatment of experimental ebola virus infections. J Infect Dis 179 Suppl 1: S224–34. 46. Wahl-Jensen V, Kurz SK, Hazelton PR, Schnittler HJ, Stroher U, et al. (2005) Role of ebola virus secreted glycoproteins and virus-like particles in activation of human macrophages. J Virol 79(4): 2413–2419. PLoS ONE | www.plosone.org 11 May 2009 | Volume 4 | Issue 5 | e5547